BWAY - BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment
BrainsWay (BWAY) announces that the U.S. FDA has granted 501k clearance for the company’s Theta Burst three-minute protocol utilizing its proprietary Deep Transcranial Magnetic Stimulation ((Deep TMS)) system for the treatment of major depressive disorder ((MDD)).The BrainsWay Theta Burst protocol will be immediately available on all BrainsWay systems already installed, the company said.Shares up more than 1% premarket.
For further details see:
BrainsWay gets FDA clearance for Deep TMS protocol in major depressive disorder treatment